C WorldWide Group Holding A S Has $10.60 Million Holdings in Shire PLC (SHPG)

C WorldWide Group Holding A S lowered its position in shares of Shire PLC (NASDAQ:SHPG) by 3.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,219 shares of the biopharmaceutical company’s stock after selling 2,626 shares during the quarter. C WorldWide Group Holding A S’s holdings in Shire PLC were worth $10,600,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Maverick Capital Ltd. lifted its holdings in Shire PLC by 19.9% during the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock valued at $320,969,000 after purchasing an additional 322,610 shares in the last quarter. Glenview Capital Management LLC lifted its holdings in Shire PLC by 69.7% during the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after purchasing an additional 707,500 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Shire PLC by 14.7% during the second quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock valued at $249,577,000 after purchasing an additional 194,059 shares in the last quarter. Boston Partners lifted its holdings in Shire PLC by 10.8% during the third quarter. Boston Partners now owns 1,455,819 shares of the biopharmaceutical company’s stock valued at $222,944,000 after purchasing an additional 141,586 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Shire PLC by 45.5% during the second quarter. Northern Trust Corp now owns 1,307,339 shares of the biopharmaceutical company’s stock valued at $216,064,000 after purchasing an additional 408,843 shares in the last quarter. 19.24% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have weighed in on SHPG. FBR & Co reaffirmed a “buy” rating and set a $201.00 price target on shares of Shire PLC in a report on Monday, October 30th. Cowen and Company set a $225.00 price target on shares of Shire PLC and gave the company a “buy” rating in a report on Sunday, October 29th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $222.00 price target on shares of Shire PLC in a report on Friday, October 27th. Zacks Investment Research raised shares of Shire PLC from a “sell” rating to a “hold” rating in a report on Friday, October 27th. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $160.00 price objective on shares of Shire PLC in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $211.00.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/12/c-worldwide-group-holding-a-s-has-10-60-million-holdings-in-shire-plc-shpg.html.

Shares of Shire PLC (NASDAQ SHPG) traded up $0.29 on Friday, reaching $140.36. 701,000 shares of the company traded hands, compared to its average volume of 1,228,033. Shire PLC has a 12 month low of $137.80 and a 12 month high of $192.15. The company has a market capitalization of $42,151.51, a PE ratio of 9.65, a PEG ratio of 0.78 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.64 by $0.17. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The company had revenue of $3.70 billion for the quarter. During the same quarter in the prior year, the firm posted $3.17 EPS. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. analysts anticipate that Shire PLC will post 15 earnings per share for the current year.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply